A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Assess the Efficacy and Safety of Difamilast Ointment 1% in Children, Adolescents, and Adults With Mild to Moderate Atopic Dermatitis
Latest Information Update: 20 Aug 2024
At a glance
- Drugs Difamilast (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Sponsors Acrotech Biopharma
- 27 Nov 2023 Status changed from active, no longer recruiting to completed.
- 02 Jun 2023 Status changed from recruiting to active, no longer recruiting.
- 10 Nov 2022 New trial record